[Why is the DNA-strand-breaker, PCNDAC, effective to solid tumors?].
Matsuda
A
A
Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Sasaki
T
T
D000818:Animals; D017209:Apoptosis; D003561:Cytarabine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000378:metabolism; D015195:Drug Design; D017353:Gene Deletion; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009336:Necrosis; D009369:Neoplasms / Q000235:genetics / Q000473:pathology*; D017354:Point Mutation; D011355:Prodrugs; D012334:RNA, Neoplasm / Q000378:metabolism
D004273:DNA, Neoplasm; D011355:Prodrugs; D012334:RNA, Neoplasm; D003561:Cytarabine; C070279:2'-cyano-2'-deoxyarabinofuranosylcytosine